Evidence map›Paper›PMID 33081788›Full record

Trial reportRespiratory research2020

Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study.

Masahiro Nemoto, Yuichiro Nei, Brian Bartholmai, Kazuki Yoshida, Hiroki Matsui, Tamao Nakashita, Shinji Motojima, Masahiro Aoshima, Jay H Ryu

Open access · goldAbstract readPragmatic Clinical Trial
In one paragraph

Trial report in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Quantitative CT in mortality prediction in pulmonary fibrosis with or without emphysema.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2021
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Masahiro NemotoDepartment of Pulmonary Medicine, Kameda Medical Center, Kamogawa, Japan. mshr.nmt.13@gmail.com.ORCID http://orcid.org/0000-0002-8413-2136
Yuichiro NeiDepartment of Rheumatology, Teikyo University Chiba Medical Center, Ichihara, Japan.
Brian BartholmaiDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Kazuki YoshidaDepartments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Hiroki MatsuiClinical Research Support Division, Kameda Institute for Health Science, Kameda College of Health Sciences, Kamogawa, Japan.
Tamao NakashitaDepartment of Rheumatology, Kameda Medical Center, Kamogawa, Japan.
Shinji MotojimaDepartment of Rheumatology, Kameda Medical Center, Kamogawa, Japan.
Masahiro AoshimaDepartment of Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo Ward, Chiba, Japan.
Jay H RyuDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Chiba University · JPKameda Medical Center · JPMayo Clinic · USHarvard University · USKameda College of Health Sciences · JPTeikyo University Chiba Medical Center · JP

Funding

Gout and Cardiovascular Comorbidities: Disentangling the Interplay with Advanced Methods to Address Measurement IssuesK23AR076453 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI YOSHIDA, KAZUKI · 2020 to 2022
$439k
NIAMS NIH HHS K23 AR076453
6 · The paper itself

Abstract

backgroundCombined pulmonary fibrosis and emphysema (CPFE) is a heterogeneous clinico-radiological syndrome without a consensus definition. There are limited data on the relation between the amount of parenchymal fibrosis and prognosis. In this study, we assessed the prognostic implications of the extent of fibrosis assessed by an automated quantitative computed tomography (CT) technique and the radiological and functional change over time in patients with a broad spectrum of fibrotic interstitial lung diseases (ILDs) encountered in a real-world setting.

methodsWe conducted a single-centre, retrospective study of 228 consecutive patients with CPFE, encountered from 2007 to 2015 at Kameda Medical Center, Chiba, Japan. We investigated the prognostic value of automated CT fibrosis quantification and the subsequent course of CPFE.

resultsAmong 228 patients with CPFE, 89 had fibrosis affecting < 5% of their lungs, 54 had 5 to < 10% fibrosis, and 85 had ≥ 10% fibrosis at the time of diagnosis. Lower volume of fibrosis correlated with lower rates of mortality and acute exacerbation (p < 0.001). In particular, among those with < 5% fibrosis, only 4.5% died and none experienced acute exacerbation during follow-up, whereas 57.6% and 29.4% of those with ≥ 10% fibrosis experienced death and acute exacerbation, respectively. Although, the ≥ 10% fibrosis group had the poorest overall survival as well as the highest incidence of acute exacerbation, the incidence of decline in pulmonary function tests, change per year in total lung volume, and progression of fibrosis on chest CT was highest in the 5 to < 10% fibrosis group. The Cox proportional hazard model for CPFE progression (defined by composite criteria of death, acute exacerbation, and decline in forced vital capacity or diffusing capacity) showed fibrosis proportion was a risk factor independent of age, sex, smoking pack-years, the Charlson Comorbidity Index, lung cancer, connective tissue disease, and idiopathic pulmonary fibrosis.

conclusionsLess severe (< 5%) fibrosis at baseline was associated with disease stability and better prognosis compared to more severe fibrosis in CPFE occurring with fibrotic ILDs. Further studies including a validation cohort will be needed. Trial Registration Retrospectively registered.

Indexed as

AgedCohort StudiesFemaleForced Expiratory VolumeHumansIdiopathic Pulmonary FibrosisMaleMiddle AgedPrognosisPulmonary EmphysemaRetrospective StudiesTomography, X-Ray ComputedCohort studiesFibrosisLungPulmonary emphysemaTomography

Identifiers

PMID33081788
PMCPMC7576807
OpenAlexW3093835604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.